Immunization with Bacillus Spores Expressing Toxin A Peptide Repeats Protects against Infection with Clostridium difficile Strains Producing Toxins A and B
Open Access
- 1 June 2011
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 79 (6), 2295-2302
- https://doi.org/10.1128/iai.00130-11
Abstract
Clostridium difficile is a leading cause of nosocomial infection in the developed world. Two toxins, A and B, produced by most strains of C. difficile are implicated as virulence factors, yet only recently has the requirement of these for infection been investigated by genetic manipulation. Current vaccine strategies are focused mostly on parenteral delivery of toxoids. In this work, we have used bacterial spores ( Bacillus subtilis ) as a delivery vehicle to evaluate the carboxy-terminal repeat domains of toxins A and B as protective antigens. Our findings are important and show that oral immunization of the repeat domain of toxin A is sufficient to confer protection in a hamster model of infection designed to closely mimic the human course of infection. Importantly, neutralizing antibodies to the toxin A repeat domain were shown to be cross-reactive with the analogous domain of toxin B and, being of high avidity, provided protection against challenge with a C. difficile strain producing toxins A and B (A + B + ). Thus, although many strains produce both toxins, antibodies to only toxin A can mediate protection. Animals vaccinated with recombinant spores were fully able to survive reinfection, a property that is particularly important for a disease with which patients are prone to relapse. We show that mucosal immunization, not parenteral delivery, is required to generate secretory IgA and that production of these neutralizing polymeric antibodies correlates with protection. This work demonstrates that an effective vaccine against C. difficile can be designed around two attributes, mucosal delivery and the repeat domain of toxin A.Keywords
This publication has 35 references indexed in Scilit:
- Treatment with Monoclonal Antibodies againstClostridium difficileToxinsThe New England Journal of Medicine, 2010
- The role of toxin A and toxin B in Clostridium difficile-associated diseaseGut Microbes, 2010
- Distinctive Profiles of Infection and Pathology in Hamsters Infected with Clostridium difficile Strains 630 and B1Infection and Immunity, 2009
- Proteomic and Genomic Characterization of Highly Infectious Clostridium difficile 630 SporesJournal of Bacteriology, 2009
- Toxin B is essential for virulence of Clostridium difficileNature, 2009
- RecombinantBacillus subtilisExpressing theClostridium perfringensAlpha Toxoid Is a Candidate Orally Delivered Vaccine against Necrotic EnteritisInfection and Immunity, 2008
- Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trialBMJ, 2007
- Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile -Induced Mortality in HamstersInfection and Immunity, 2006
- Active and passive immunization against Clostridium difficile diarrhea and colitisVaccine, 2004
- Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin AInfection and Immunity, 2003